AstraZeneca’s Farxiga scores a speedy FDA review in kidney disease—and gets another jump on rival Jardiance

AstraZeneca’s Farxiga scores a speedy FDA review in kidney disease—and gets another jump on rival Jardiance
esagonowsky
Wed, 01/06/2021 – 11:18